Rise in serum PSA of 1.5 ng/mL above 24-month nadir after external beam radiotherapy is predictive of biochemical failure

Urology

Volumn 63, Issue 6, 2004, Pages 1132-1137

  Kamat, Ashish M ^b   Rosser, Charles J ^b   Levy, Lawrence B ^b   Chichakli, Ramsey ^b   Lee, Andrew K ^b   Cheung, Min Rex ^b   Pisters, Louis L ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BEAM THERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DATA ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE MARKER; EVALUATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MEDICAL SOCIETY; PREDICTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; TREATMENT FAILURE;

AGED; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL;

EID: 2942579934     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2004.01.010     Document Type: Article

References (12)

1. Zagars G.K., Sherman N.E., Babaian R.J. Prostate-specific antigen and external beam radiation therapy in prostate cancer. Cancer. 67:1991;412-420
2. Zagars G.K., Pollack A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol. 44:1997;213-221
3. Hanks G.E., D'Amico A., Epstein B.E., et al. Prostate-specific antigen doubling times in patients with prostate cancer a potentially useful reflection of tumor doubling time. Int J Radiat Oncol Biol Phys. 27:1993;125-127
4. Pollack A., Zagars G.K., Kavadi V.S. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer. 74:1994;670-678
5. Hanks G.E., Hanlon A.L., Schultheiss T.E., et al. Conformal external beam treatment of prostate cancer. Urology. 50:1997;87-92
6. Rosser C.J., Kuban D.A., Levy L.B., et al. Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer. J Urol. 168:2002;2001-2005
7. Horwitz E.M., Vicini F.A., Ziaja E.L., et al. Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control. Int J Radiat Oncol Biol Phys. 36:1996;565-571
8. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 37:1997;1035-1041
9. Zagars G.K., Pollack A., Kavadi V.S., et al. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 32:1995;293-306
10. Kavadi V.S., Zagars G.K., Pollack A. Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer prognostic implications. Int J Radiat Oncol Biol Phys. 30:1994;279-287
11. Hanlon A.L., Hanks G.E. for the American Society for Therapeutic Radiology and Oncology. Scrutiny of the ASTRO consensus definition of biochemical failure in irradiated prostate cancer patients demonstrates its usefulness and robustness. Int J Radiat Oncol Biol Phys. 46:2000;559-566
12. McMullen K.P., Lee W.R. A structured literature review to determine the use of the American Society for Therapeutic Radiology and Oncology consensus definition of biochemical failure. Urology. 61:2003;391-396